TREŚĆ SPONSOROWANA
Współistnienie przewlekłej choroby żylnej z chorobą tętnic obwodowych
Zapisuję
Zapisz
Zapisane
Przewlekła choroba żylna (CVD, chronic venous disease) i choroba tętnic obwodowych (PAD, peripheral arterial disease) często współistnieją, co wynika ze wspólnego patomechanizmu chorób naczyń tętniczych i żylnych. Diagnostyka obu schorzeń jest stosunkowo prosta – rozpoznanie CVD i PAD można postawić w oparciu o dokładne badanie podmiotowe i przedmiotowe. Identyfikacja wymienionych schorzeń jest istotna z uwagi na możliwość wczesnego wdrożenia leczenia, co wpływa na poprawę rokowania.
Glikokaliks – funkcja ochronna i następstwa uszkodzenia
Źródła
- Milusev, A., Rieben, R., & Sorvillo, N. (2022). The Endothelial Glycocalyx: A Possible Therapeutic Target in Cardiovascular Disorders. Frontiers in cardiovascular medicine, 9, 897087. https://doi.org/10.3389/fcvm.2022.897087
- Moore, K. H., Murphy, H. A., & George, E. M. (2021). The glycocalyx: a central regulator of vascular function. American journal of physiology. Regulatory, integrative and comparative physiology, 320(4), R508–R518. https://doi.org/10.1152/ajpregu.00340.2020
- Salim, S., Machin, M., Patterson, B. O., Onida, S., & Davies, A. H. (2021). Global Epidemiology of Chronic Venous Disease: A Systematic Review With Pooled Prevalence Analysis. Annals of surgery, 274(6), 971–976. https://doi.org/10.1097/SLA.0000000000004631
- Jawien A. (2003). The influence of environmental factors in chronic venous insufficiency. Angiology, 54 Suppl 1, S19–S31. https://doi.org/10.1177/0003319703054001S04
- Urbanek, T., Dorobisz, A., Gabriel, M., Hendiger, W., Jawień, A., & Kucharzewski, M. et al. (2015). Assessment of public awareness in the field of epidemiology, prevention and treatment of chronic venous diseases in Poland. Phlebological Review, 23(2), 45-53. https://doi.org/10.5114/pr.2015.54035
- Pannier-Fischer, F., Bromen, K., Schuldt, K., Stang, A., Poncar, C., Wittenhorst, M., Bock, E., Weber, S., Jöckel, K., & Rabe, E. (2003). Bonner Venenstudie der Deutschen Gesellschaft für Phlebologie. Phlebologie, 32(01), 1–14. https://doi.org/10.1055/s-0037-1617353
- Hiatt W. R. (2001). Medical treatment of peripheral arterial disease and claudication. The New England journal of medicine, 344(21), 1608–1621. https://doi.org/10.1056/NEJM200105243442108
- Regensteiner, J. G., & Hiatt, W. R. (2002). Current medical therapies for patients with peripheral arterial disease: a critical review. The American journal of medicine, 112(1), 49–57. https://doi.org/10.1016/s0002-9343(01)01034-8
- Prochaska, J. H., Arnold, N., Falcke, A., Kopp, S., Schulz, A., Buch, G., Moll, S., Panova-Noeva, M., Jünger, C., Eggebrecht, L., Pfeiffer, N., Beutel, M., Binder, H., Grabbe, S., Lackner, K. J., Ten Cate-Hoek, A., Espinola-Klein, C., Münzel, T., & Wild, P. S. (2021). Chronic venous insufficiency, cardiovascular disease, and mortality: a population study. European heart journal, 42(40), 4157–4165. https://doi.org/10.1093/eurheartj/ehab495
- Ammermann, F., Meinel, F. G., Beller, E., Busse, A., Streckenbach, F., Teichert, C., Weinrich, M., Neumann, A., Weber, M. A., & Heller, T. (2020). Concomitant chronic venous insufficiency in patients with peripheral artery disease: insights from MR angiography. European radiology, 30(7), 3908–3914. https://doi.org/10.1007/s00330-020-06696-x
- Raffetto J. D. (2018). Pathophysiology of Chronic Venous Disease and Venous Ulcers. The Surgical clinics of North America, 98(2), 337–347. https://doi.org/10.1016/j.suc.2017.11.002
- Writing Committee Members, Gornik, H. L., Aronow, H. D., Goodney, P. P., Arya, S., Brewster, L. P., Byrd, L., Chandra, V., Drachman, D. E., Eaves, J. M., Ehrman, J. K., Evans, J. N., Getchius, T. S. D., Gutiérrez, J. A., Hawkins, B. M., Hess, C. N., Ho, K. J., Jones, W. S., Kim, E. S. H., Kinlay, S., … Wilkins, L. R. (2024). 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 83(24), 2497–2604. https://doi.org/10.1016/j.jacc.2024.02.013
- Jawień, A., Filipiak, K. J., Doroszko, A., Dzieciątkowski, T., Krasiński, Z., Szymański, F. M., & Terlecki, P. (2023). Kompleksowa opieka nad pacjentem z chorobą naczyń obwodowych tętnic i żył — rekomendacje zespołu ekspertów 2023. Acta Angiologica, 29(2), 1–60. https://doi.org/10.5603/aa.2023.0008
- Fiore, G., Baraldi, A., Gambarotta, G.C. (1992). Inhibition of plasminoagen activator (PAI-1) by sulodexide in post-thrombophlebotic patients. J Drug Invest. 3. 173–178.
- Coccheri S. (2014). Biological and clinical effects of sulodexide in arterial disorders and diseases. International angiology : a journal of the International Union of Angiology, 33(3), 263–274.
- Broekhuizen, L. N., Lemkes, B. A., Mooij, H. L., Meuwese, M. C., Verberne, H., Holleman, F., Schlingemann, R. O., Nieuwdorp, M., Stroes, E. S., & Vink, H. (2010). Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia, 53(12), 2646–2655. https://doi.org/10.1007/s00125-010-1910-x
- Masola, V., Onisto, M., Zaza, G., Lupo, A., & Gambaro, G. (2012). A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. Journal of translational medicine, 10, 213. https://doi.org/10.1186/1479-5876-10-213
- Bignamini, A. A., Chebil, A., Gambaro, G., & Matuška, J. (2021). Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis. Advances in therapy, 38(3), 1483–1513. https://doi.org/10.1007/s12325-021-01620-1
- Cospite, M., Ferrara, F., Cospite, V., & Palazzini, E. (1992). Sulodexide and the microcirculatory component in microphlebopathies. Current medical research and opinion, 13(1), 56–60. https://doi.org/10.1185/03007999209115223
- Shu, J., Zeng, L. Y., Lin, K. Y., Mu, P. W., Zhang, G. C., Chen, Y. M., & Wang, M. M. (2009). Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 29(4), 778–780.
- Coccheri, S., Scondotto, G., Agnelli, G., Palazzini, E., Zamboni, V., & Arterial Arm of the Suavis (Sulodexide Arterial Venous Italian Study) group (2002). Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. European heart journal, 23(13), 1057–1065. https://doi.org/10.1053/euhj.2001.3033
- Gaddi, A. V., Capello, F., Gheorghe-Fronea, O. F., Fadda, S., & Darabont, R. O. (2020). Sulodexide improves pain-free walking distance in patients with lower extremity peripheral arterial disease: A systematic review and meta-analysis. JRSM cardiovascular disease, 9, 2048004020907002. https://doi.org/10.1177/2048004020907002
- Condorelli, M., Chiariello, M., Dagianti, A., Penco, M., Dalla Volta, S., Pengo, V., Schivazappa, L., Mattioli, G., Mattioli, A. V., & Brusoni, B. (1994). IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. Journal of the American College of Cardiology, 23(1), 27–34. https://doi.org/10.1016/0735-1097(94)90498-7
- Bikdeli, B., Chatterjee, S., Kirtane, A. J., Parikh, S. A., Andreozzi, G. M., Desai, N. R., Francese, D. P., Gibson, C. M., Piazza, G., Goldhaber, S. Z., Eikelboom, J. W., Krumholz, H. M., & Stone, G. W. (2020). Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. Seminars in thrombosis and hemostasis, 46(8), 908–918. https://doi.org/10.1055/s-0040-1716874
Polecane artykuły